Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.
Translational Immunology Research Program (TRIMM), University of Helsinki, Helsinki, Finland.
Cancer Sci. 2019 Nov;110(11):3424-3433. doi: 10.1111/cas.14189. Epub 2019 Sep 30.
Tongue squamous cell carcinoma (TSCC) has a poor prognosis due to its early metastasis through blood and lymphatic vessels. We undertook a systematic review to investigate the prognostic significance of blood microvessel density (MVD) and lymphatic vessel density (LVD) in TSCC patients. We carried out a systematic search in Ovid Medline, Scopus, and Cochrane libraries. All studies that evaluated the prognostic significance of MVD/LVD markers in TSCC were systematically retrieved. Our results showed that MVD/LVD markers, CD31, CD34, CD105, factor VIII, lymphatic vessel endothelial hyaluronan receptor-1, and D2-40 were evaluated in TSCC patients until 28 June 2018. Six out of 13 studies reported markers that were associated with poor prognosis in TSCC. Two out of three studies suggested that a high number of D2-40 vessels predicated low overall survival (OS); the third study reported that the ratio of D2-40 over factor VIII vessels is associated with low OS. Most of the other markers had controversial results for prognostication. We found higher expression of MVD/LVD markers were commonly, but not always, associated with shorter survival in TSCC patients. It is therefore not currently possible to recommend implementation of these markers as reliable prognosticators in clinical practice. More studies (especially for D2-40) with larger patient cohorts are needed.
舌鳞状细胞癌 (TSCC) 由于其通过血液和淋巴管早期转移,预后较差。我们进行了一项系统评价,以调查血液微血管密度 (MVD) 和淋巴管密度 (LVD) 在 TSCC 患者中的预后意义。我们在 Ovid Medline、Scopus 和 Cochrane 图书馆中进行了系统检索。系统检索了所有评估 MVD/LVD 标志物在 TSCC 中预后意义的研究。我们的结果表明,直到 2018 年 6 月 28 日,已经评估了 CD31、CD34、CD105、VIII 因子、淋巴管内皮透明质酸受体-1 和 D2-40 等 MVD/LVD 标志物在 TSCC 患者中的应用。13 项研究中有 6 项报告了与 TSCC 预后不良相关的标志物。3 项研究中有 2 项表明 D2-40 血管数量多预示着总生存率(OS)低;第 3 项研究报告称,D2-40 与 VIII 因子血管的比值与低 OS 相关。其他大多数标志物的预后结果存在争议。我们发现 MVD/LVD 标志物的高表达通常与 TSCC 患者的生存期缩短有关,但并非总是如此。因此,目前还不能推荐将这些标志物作为可靠的预后指标在临床实践中应用。需要更多具有更大患者队列的研究(特别是针对 D2-40)。